JP2842888B2 - リボヌクレアーゼインヒビターを有効成分とする癌細胞転移抑制剤 - Google Patents

リボヌクレアーゼインヒビターを有効成分とする癌細胞転移抑制剤

Info

Publication number
JP2842888B2
JP2842888B2 JP1126387A JP12638789A JP2842888B2 JP 2842888 B2 JP2842888 B2 JP 2842888B2 JP 1126387 A JP1126387 A JP 1126387A JP 12638789 A JP12638789 A JP 12638789A JP 2842888 B2 JP2842888 B2 JP 2842888B2
Authority
JP
Japan
Prior art keywords
inhibitor
day
ribonuclease inhibitor
mouse
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP1126387A
Other languages
English (en)
Japanese (ja)
Other versions
JPH02306922A (ja
Inventor
紘司 福島
勉 本庄
知信 藤田
晴久 藤田
敏晴 桜井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MORINAGA SEIKA KK
Original Assignee
MORINAGA SEIKA KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MORINAGA SEIKA KK filed Critical MORINAGA SEIKA KK
Priority to JP1126387A priority Critical patent/JP2842888B2/ja
Priority to US07/416,066 priority patent/US5175005A/en
Priority to DE3935132A priority patent/DE3935132A1/de
Priority to FR8914226A priority patent/FR2647017A1/fr
Priority to GB8924450A priority patent/GB2231793B/en
Publication of JPH02306922A publication Critical patent/JPH02306922A/ja
Application granted granted Critical
Publication of JP2842888B2 publication Critical patent/JP2842888B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y10S530/851—Placenta; amniotic fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP1126387A 1989-05-19 1989-05-19 リボヌクレアーゼインヒビターを有効成分とする癌細胞転移抑制剤 Expired - Fee Related JP2842888B2 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP1126387A JP2842888B2 (ja) 1989-05-19 1989-05-19 リボヌクレアーゼインヒビターを有効成分とする癌細胞転移抑制剤
US07/416,066 US5175005A (en) 1989-05-19 1989-10-02 Method of controlling lung tumor cell metastasis
DE3935132A DE3935132A1 (de) 1989-05-19 1989-10-18 Antitumormittel, mittel zum unterdruecken von tumorzellmetastasen und verfahren zum behandeln von krebs und zum kontrollieren von tumorzellmetastasen
FR8914226A FR2647017A1 (fr) 1989-05-19 1989-10-30 Agent antitumoral et agent antimetastatique contenant un inhibiteur de la ribonuclease comme composant actif
GB8924450A GB2231793B (en) 1989-05-19 1989-10-31 Metastatis suppressive agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1126387A JP2842888B2 (ja) 1989-05-19 1989-05-19 リボヌクレアーゼインヒビターを有効成分とする癌細胞転移抑制剤

Publications (2)

Publication Number Publication Date
JPH02306922A JPH02306922A (ja) 1990-12-20
JP2842888B2 true JP2842888B2 (ja) 1999-01-06

Family

ID=14933885

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1126387A Expired - Fee Related JP2842888B2 (ja) 1989-05-19 1989-05-19 リボヌクレアーゼインヒビターを有効成分とする癌細胞転移抑制剤

Country Status (5)

Country Link
US (1) US5175005A (enExample)
JP (1) JP2842888B2 (enExample)
DE (1) DE3935132A1 (enExample)
FR (1) FR2647017A1 (enExample)
GB (1) GB2231793B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529775A (en) * 1988-04-06 1996-06-25 Alfacell Corporation Compositions comprising ONCONASE(™) and cisplatin, melphalan, or doxorubicin HCl
DK1156043T3 (da) * 1992-07-24 2004-03-01 Univ California Lægemidler, der forøger synaptiske reaktioner formidlet af ampa-receptorer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552888A (en) * 1982-01-15 1985-11-12 Eli Lilly And Company Ascorbic acid ethers in angiogene
US4599331A (en) * 1984-12-24 1986-07-08 Syntex (U.S.A.) Inc. Etianic acids as antiangiogenics
US5019556A (en) * 1987-04-14 1991-05-28 President And Fellows Of Harvard College Inhibitors of angiogenin
US4966964A (en) * 1987-04-14 1990-10-30 President And Fellows Of Harvard College Inhibitors of angiogenin
DE3884853T2 (de) * 1987-04-14 1994-02-03 Harvard College Angiogenininhibitoren.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｂｒ．Ｊ．Ｃａｎｃｅｒ，Ｖｏｌ．５７，Ｎｏ．６（１９８８）ｐ．５８７−５９０
Ｐｒｏｃ．Ｎａｔｌ．Ａｃａｄ．Ｓｃｉ．ＵＳＡ，Ｖｏｌ．８４（１９８７）ｐ．２２３８−２２４１

Also Published As

Publication number Publication date
GB2231793B (en) 1993-10-06
JPH02306922A (ja) 1990-12-20
DE3935132A1 (de) 1990-11-22
FR2647017B1 (enExample) 1994-08-19
GB8924450D0 (en) 1989-12-20
GB2231793A (en) 1990-11-28
FR2647017A1 (fr) 1990-11-23
US5175005A (en) 1992-12-29

Similar Documents

Publication Publication Date Title
JP5355856B2 (ja) Ｖｅｇｆアンタゴニストおよび抗増殖性薬剤の組成物ならびに癌の処置のためのその使用
Senkevitch et al. Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations
WO1999051246A1 (en) Antitumor agents
JP2008120827A (ja) アミノイミダゾールカルボキサミドの塩による腫瘍の治療および阻止
JP2020537695A (ja) ストレプトニグリンおよびラパマイシンを有効成分として含む、癌の予防または治療用薬学的組成物
JP2007501239A (ja) 放射線治療と組み合わせたｖｅｇｆアンタゴニストの使用
JP2001509479A (ja) ヌクレオチド含有組成物
US20050196340A1 (en) Use of a VEGF antagonist in combination with radiation therapy
JP2842888B2 (ja) リボヌクレアーゼインヒビターを有効成分とする癌細胞転移抑制剤
JP2006523664A5 (enExample)
JP3199081B2 (ja) 抗腫瘍剤
CN110151748A (zh) 一种用于治疗前列腺癌的药物组合物
MXPA02000915A (es) Composiciones que contienen agentes activos derivados de musculo.
WO2000043403A1 (en) 2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes
Stratton et al. Response of human adenocarcinoma to chemotherapy: as sole agents and in combination with sodium ibuprofen
JP2579132B2 (ja) 癌細胞転移阻害剤
JPH0460093B2 (enExample)
Frasci et al. Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triplet combination in anthracycline-and taxane-refractory breast cancer patients: a Southern Italy Cooperative Oncology Group phase I/II study
TWI656131B (zh) Ｎｒｆ－１蛋白質用以製備治療膀胱癌之藥物的用途
JP2001508810A (ja) 静脈内エストラムスチンリン酸の有効性を高める方法
JP4395901B2 (ja) 新規遺伝子治療用薬剤
Liu et al. Virulizin (R)-2gamma
CA2469613A1 (en) Process for affecting neurologic progression
Badgwell et al. Intra-arterial administration of TNF-α followed by arterial ablation is an effective therapy for a regionally confined TNF-resistant rat mammary adenocarcinoma
US20030139582A1 (en) Composition containing biologically active polypeptides suitable for the oral administration

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees